“Researchers at Johns Hopkins University are conducting the first clinical trials to evaluate the potential of a pinworm medication for the treatment of children and adults with newly diagnosed glioblastoma.
“Mebendazole has been used for more than 40 years to treat parasitic infections.
“Although the medication requires further testing in patients with cancer, results of a phase 1 trial have shown the medication is safe for and tolerated by adults with glioblastoma. An additional phase 1 trial is underway to assess the agent in children.”
“A treatment regimen that included the inexpensive anti-malaria drug chloroquine dramatically improved survival and quality of life for three patients with glioblastoma, according to researchers from University of Colorado Cancer Center.
“Two of the patients maintained response to treatment for more than 2 years.
” ‘We were excited that the three patients who tried the combination all had some clinical benefit,’ Jean Mulcahy Levy, MD, investigator at University of Colorado Cancer Center and pediatric oncologist at Children’s Hospital Colorado, told HemOnc Today. ‘This supports examining this combination in a broader clinical trial and assessing its efficacy in a larger patient population.’ ”
“The most common type of malignant childhood brain cancer has been identified as seven separate conditions each needing a different treatment, new research has revealed.
“A study by Newcastle and Northumbria universities has found that childhood medulloblastoma can be separated into seven different subgroups which all have their own biological and clinical characteristics.”
“Immunomic Therapeutics has entered an exclusive licensing agreement with Annias Immunotherapeutics for the rights to use Annia’s intellectual property regarding an immunotherapy based on antigens of cytomegalovirus (CMV). Both companies are developing new approaches for generating vaccines for cancer.
“Under the new licensing agreement, Immunomic will be able to combine LAMP-Vax, itsinvestigational nucleic acid-based immunotherapy platform, with Annia’s CMV immunotherapy platform. Duke University’s John H. Sampson, MD, PhD, and Duane A. Mitchell, MD, PhD, developed this platform, which was later licensed to Annias.”
“Seasonal influenza vaccination resulted in increased risk of immune-related adverse events (AEs) in lung cancer patients treated with PD-1/PD-L1 checkpoint inhibitors in a small study. However, the risks of the flu itself may still outweigh the risks associated with vaccination.
” ‘Use of immune checkpoint inhibitors is now standard clinical practice for many oncology patients, and these same patients—particularly those with lung cancer—also face increased risk for complications from influenza,’ said Sacha Rothschild, MD, PhD, of University Hospital Basel in Switzerland, in a press release. ‘Although routine influenza vaccination has long been recommended for cancer patients, there are concerns that it might trigger an exaggerated immune response in this subgroup receiving checkpoint inhibitors.’ ”
“Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with glioblastoma, according to the final results of a phase III trial presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting. Patients treated with tumor-treating fields plus temozolomide had a 37% reduced risk of death compared with those randomized to receive temozolomide alone.”
Stephen Western is a dedicated advocate for people dealing with brain cancer. He started this work in February 2013, when his friend was diagnosed with a type of brain tumor known as an astrocytoma. In order to help her, he began to learn all he could about the science of astrocytoma treatment.
Stephen soon realized that many more patients might benefit from his growing knowledge, so he created the website Astrocytoma Options to share this information and update it as new research emerges. He also helps run another site that focuses on the multi-drug “cocktails” often used in brain tumor treatment.
Although Stephen has no formal scientific training, he is able to help patients better understand their treatment options and stay up-to-date on the latest treatment research. To learn more about his work, I interviewed him via email:Continue reading…
“The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer. The products are marketed and sold without FDA approval, most commonly on websites and social media platforms.
” ‘Consumers should not use these or similar unproven products because they may be unsafe and could prevent a person from seeking an appropriate and potentially life-saving cancer diagnosis or treatment,’ said Douglas W. Stearn, director of the Office of Enforcement and Import Operations in the FDA’s Office of Regulatory Affairs. ‘We encourage people to remain vigilant whether online or in a store, and avoid purchasing products marketed to treat cancer without any proof they will work. Patients should consult a health care professional about proper prevention, diagnosis and treatment of cancer.’ ”